Full Title: Pipeline Insight: Non-insulin antidiabetics - Incretin mimetics - leaders in a diverse pipeline
Introduction
Datamonitor expects incretin mimetics to emerge as a major new therapeutic class in non-insulin antidiabetics, driven by an explosion in the patient population, safety fears surrounding established therapies and significant unmet patient needs.
Scope
Comprehensive analysis of the current non-insulin antidiabetic pipeline detailing the broad range of developmental classes.
A detailed clinical and commercial assessment of all key emerging therapies.
Sales based sales forecasts for key late-stage developmental non-insulin antidiabetics agents in the seven major markets to 2017.
Highlights
Incretin mimetics, GLP-1 agonists and DPP-IV inhibitors, are likely to be the most successful candidates in the pipeline. Pipeline incretin candidates are forecast to generate sales of $7,905m in the seven major markets in 2017 A huge number of molecules are in development as non-insulin antidiabetics to meet the increase in patient population and disease unmet needs. 137 candidates from 60 different mechanisms of action are in development Big Pharma dominate the non-insulin antidiabetic pipeline as the disease is one of the few growth areas in the cardiovascular and metabolic disease areas. Sixteen of the top twenty drug companies have a non-insulin antidiabetic pipeline and between them are developing 52% of the pipeline
Reasons to Purchase
Quantify the future drugs in the non-insulin antidiabetic market.
Identify licensing opportunities based on company portfolio and market needs.
Assess the remaining market opportunity, where established therapies and other developmental compounds fail to address key unmet clinical needs.
.gif)
.gif)